Tenon Medical Q2 revenue jumps on higher surgical procedure volume
TNON•Outlook and result drivers
- Company expects lower per-procedure costs following instrument upgrades to Catamaran SI Joint Fusion System
- Tenon Medical plans to use offering proceeds for debt repayment, commercial expansion, and clinical research
- Company focus for remainder of 2026 is accelerating product launches, expanding training, and controlling spending
Result drivers
- Surgical procedure volume - Co said Q2 revenue growth was primarily driven by a significant increase in the number of surgical procedures, including SImmetry+ system contributions
- Gross margin improvement - Co attributed 21-point gross margin increase to higher revenue and lower fixed costs, leading to further absorption of production overhead costs
- FDA clearance impact - FDA clearance for updated Catamaran system expected to reduce recurring per-procedure costs by shifting instruments from disposable to reusable
Q2 revenue rises on higher surgical procedure volume
- US medical device maker's Q2 revenue rose 127% yr/yr on higher surgical procedure volume
- Q2 gross profit up 232% yr/yr, gross margin improved to 64% from 43%
- Company closed $4.2 mln public offering and received FDA clearance for updated Catamaran system
